




RealRate

## PHARMACEUTICAL 2022

ALNYLAM PHARMACEUTICALS INC.  
Rank 361 of 466

Alnylam@20



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 30% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 4.9%, being 73% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	2,808,576
Cost of Goods Sold	115,005
Intangible Assets	0
Liabilities, Current	695,710
Liabilities, Non-Current	532,670
Other Assets	332,770
Other Compr. Net Income	10,363
Other Expenses	25,819
Other Liabilities	1,826,721
Other Net Income	-143,492
Other Revenues	844,287
Property and Equipment	501,958
Research and Development	792,156
Selling, General and Administrative Expense	620,639

Output Variable	Value in 1000 USD
Assets	3,643,304
Liabilities	3,055,101
Expenses	1,553,619
Revenues	844,287
Stockholders Equity	588,203
Net Income	-852,824
Comprehensive Net Income	-847,642
Economic Capital Ratio	4.9%